Clinical Trial

DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau

Study acronym: DU-PRISM
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection. The study will evaluate how well the vaccine is tolerated and whether it produces antibodies against Alzheimer's disease-related proteins.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-19; most recent amendment 2025-10-20.
Trial Details
NCT Number NCT07142278
Lead Sponsor Nuravax, Inc.
Collaborators: National Institute on Aging (NIA), Institute for Molecular Medicine
Conditions Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
Enrollment 24 participants
Start Date 2025-11-01
Primary Completion 2027-04-01 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-22